Pfizer’s RA drug, tofacitinib, gains approval in several additional countries
Pfizer announced yesterday that its rheumatoid arthritis treatment, tofacitinib, has obtained approval for patients with inadequate response to current therapies in several additional countries globally, including Switzerland, Argentina, Kuwait, UAE and Russia. The drug has already been approved in the US.
Switzerland, the first European country to receive approval, saw approval by Swissmedic – the Swiss agency for therapeutic products.
It will be known under its brand name, XELJANZ, except in Russia, where the brand name will be Jaquinus®.
XELJANZ is a novel, oral Janus kinase (JAK) inhibitor and is the first approved RA treatment in its class of drugs.
Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.